Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07551479

SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer

In this prospective, multicentre, randomized phase III trial, 612 locally advanced rectal cancer (LARC, T3-4/N+M0) patients with at least one high-risk features (lower location (≤5cm), cT4, cN2, MRF+, EMVI+, TD+) will be included, and randomly assigned to TNT group and iTNT group (1:1). TNT group receives long-course chemoradiotherapy (50Gy/25Fx concurrent with oral capecitabine) followed by 6 cycles of CAPOX. iTNT group receives short-course radiotherapy (25Gy/5Fx) followed by 6 cycles of Serplulimab combined with CAPOX. After the efficacy evaluation, the patients who achieves clinical complete response (cCR) will be managed by a watch and wait (W&W) protocol and non-cCR patients will be recommended surgery. The primary endpoint is 3-year event-free survival rate (3yEFS%). The secondary endpoints include the complete response (CR, pathological complete response [pCR] plus cCR) rate, 3-year organ preservation rate, 3-year disease-free survival rate (3yDFS%), 3-year local recurrence free survival rate (3yLRFS%), 3-year distant metastasis free survival rate (3yDMFS%), 3-year overall survival rate (3yOS%), grade 3-4 acute adverse effects (AE) rate, rate of surgical complications, anal functions and quality of life, etc.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18-75 years old, female and male;
  • Pathological confirmed adenocarcinoma;
  • The distance from anal verge ≤ 10 cm;
  • MSI/MMR status: MSS/pMMR;
  • Clinical stage T3-4 and/or N+, without distance metastases;
  • At least one of the following factors is present: distance from the anus ≤5 cm, cT4, cN2, positive cMRF, positive cEMVI, positive tumor deposit or positive lateral lymph node;
  • KPS ≥ 70;
  • No radiotherapy, chemotherapy, immunotherapy, or any other anti-tumor therapy had been administered prior to enrollment;
  • Baseline blood and biochemical indicators meet the following criteria: neutrophils ≥ 1.5 × 10^9/L, Hb ≥ 90 g/L, PLT ≥ 100 × 10^9/L, ALT/ AST ≤ 2.5 ULN, Cr ≤ 1 ULN;
  • With good compliance and signed the consent form.

Exclusion criteria

  • Pregnancy or breast-feeding women;
  • Known history of other malignancies within 5 years;
  • Known history of severe neurological or mental illness (such as schizophrenia, dementia or epilepsy);
  • Current severe cardiac disease (cardiac dysfunction and arrhythmia), renal dysfunction and liver dysfunction;
  • Acute cardiac infarction or cerebral ischemic stroke occurred within 6 months before recruitment;
  • Uncontrolled infection which needs systemic therapy;
  • Active autoimmune disease or immunodeficiencies, known history of organ transplantation or systematic use of immunosuppressive agents;
  • Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1 to 2 antibody positive), active syphilis infection, active pulmonary tuberculosis infection;
  • Allergic to any component of the therapy.

Treatment and study plan

short-course radiaotherapy

Radiation

short-course radiaotherapy (25Gy/5Fx)

long-course chemoradiaothearpy

Radiation

long-course chemoradiotherapy (50Gy/25Fx concurrent with oral capecitabine 825mg/m2 bid d1-5 qw)

Capecitabine

Drug

Capecitabine: 1000mg/m2 bid d1-14 q3w

Oxaliplatin

Drug

Oxaliplatin 130mg/m2 d1 q3w

PD-1 inhibitor

Drug

Serplulimab 300mg d1 q3w

Primary outcomes

  1. 3 year event-free survival rate

    Time frame: From date of randomization until the date of first documented early local failure, disease progression during neoadjuvant therapy, pelvic recurrence, distant metastasis, or death, whichever came first, assessed up to 36 months.

    Rate of 3 year event free survival

Secondary outcomes

  1. Complete response (CR) rate

    Time frame: 1 month after the surgery or the decision of W&W

    Rate of complete response (CR), including the rate of pathologic complete response (pCR) after surgery and the rate of cCR with W&W strategy.

  2. 3 year organ preservation rate

    Time frame: From date of randomization until the resection of rectum or anus, assessed up to 36 months.

    3 year organ preservation rate

  3. 3 year disease free survival rate

    Time frame: From date of randomization until the date of first documented recurrence and metastasis after the completion of treatment or death from any cause, whichever came first, assessed up to 36 months.

    Rate of 3 year disease free survival

  4. 3 year local recurrence free survival rate

    Time frame: From date of randomization until the date of first documented pelvic failure, assessed up to 36 months.

    Rate of 3 year local recurrence free survival

  5. 3 year distant metastasis free survival rate

    Time frame: From date of randomization until the date of first documented distant metastasis, assessed up to 36 months.

    Rate of 3 year distant metastasis free survival

  6. 3 year overall survival rate

    Time frame: From date of randomization until the date of death from any cause, assessed up to 36 months.

    Rate of 3 year overall survival

  7. Grade 3-4 adverse effects rate

    Time frame: From date of randomization until 3 months after the completion neoadjuvant therapy

    Rate of chemotherapy, radiotherapy and immunotherapy related adverse events

  8. Rate of surgical complications

    Time frame: The surgical complications were assessed within 1 year after the surgery.

    Rate of surgical complications

  9. Low Anterior Resection Syndrome Score

    Time frame: From date of randomization until five years after the completion of treament.

    Evaluating the anal function using Low Anterior Resection Syndrome (LARS) score(range 0-42, with higher scores representing worse anal function)

  10. Wexner Continence Grading Scale

    Time frame: From date of randomization until five years after the completion of treament.

    Evaluating the anal function using Wexner Continence Grading Scale (range 1-20, with higher scores representing worse anal function)

Study contacts

Contact information is provided by the study sponsor or research team.

Zhen Zhang, MD, PhD

CONTACT

[email protected]

18801735029

Sponsors and collaborators

Lead sponsor

Fudan University

Other

Registry information

Official study title

SCRT Followed by CAPOX and PD-1 Inhibitor Versus LCCRT Followed by CAPOX in Total Neoadjuvant Treatment for High-risk LARC: A Prospective, Randomized, Multicenter, Phase III Study

Acronym: TORCH-STAR

Important dates

Study start
2026
Primary completion
2032
Study completion
2035
First posted
Apr 24, 2026
Registry last updated
Apr 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.